*Egypt. J. Chem.* **Vol. 67**, No. 11 pp. 71 - 81 (2024)

**Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy**

**Samar Ebrahim Ghanem1, Ibrahim El Tantawy El Sayed2, Ashraf A Basuni1\*, Dalia El Sabaawy3, Abd El-Hamid A. Ismail4, Rofaida Mohamed Elhawary2, Nashwa Abuel-Fetuh Shebl5, Warda Othman Saad5**

*1 Department of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University 2Chemistry Department, Faculty of Science, Menoufia University* *3Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia* *University 4Department of Organic Chemistry, Faculty of Science, Menoufia University 5Hepatology and Gastroenterology department, National Liver Institute, Menoufia* *University*

**Supporting information**

**Supplementary table 1. Comparison among the different groups regarding laboratory results**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | De-novo HCC(n = 70) | Post-DAAs HCC(n = 50) | DAAs treated HCV(n = 60) | Control(n = 40) | Test of sig. | P value |
| ALT |  |  |  |  |  |  |
| Min. – Max. | 12.0 – 168.0 | 10.0 – 66.0 | 14.0 – 114.0 | 10.0 – 23.0 | H=95.839\* | <0.001\* |
| Mean ± SD. | 63.10 ± 37.43 | 27.84 ± 13.40 | 35.65 ± 19.49 | 16.38 ± 3.66 |
| Median (IQR) | 55.0 (28.0 – 85.0) | 23.0 (18.0 – 35.0) | 33.0 (22.0 – 41.0) | 17.0 (13.0 – 19.0) |
| p1 | <0.001\* | <0.001\* | <0.001\* |  |  |  |
| Sig. bet. groups | p2<0.001\*, p3<0.001\*, p4=0.035\* |  |  |  |
| AST |  |  |  |  |  |  |
| Min. – Max. | 15.0 – 149.0 | 14.0 – 80.0 | 18.0 – 86.0 | 10.0 – 23.0 | H=96.785\* | <0.001\* |
| Mean ± SD. | 63.33 ± 35.77 | 36.28 ± 17.41 | 34.62 ± 14.96 | 16.60 ± 3.81 |
| Median (IQR) | 57.50 (33.0 – 84.0) | 35.50 (23.0 – 46.0) | 31.50 (24.0 – 38.0) | 17.0 (13.0 – 20.0) |
| p1 | <0.001\* | <0.001\* | <0.001\* |  |  |  |
| Sig. bet. groups | p2<0.001\*, p3<0.001\*, p4=0.984 |  |  |  |
| T.B |  |  |  |  |  |  |
| Min. – Max. | 0.50 – 3.20 | 0.30 – 3.90 | 0.30 – 1.50 | 0.30 – 0.60 | H=95.589\* | <0.001\* |
| Mean ± SD. | 1.14 ± 0.62 | 1.11 ± 0.77 | 0.61 ± 0.27 | 0.42 ± 0.08 |
| Median (IQR) | 0.93 (0.70 – 1.40) | 0.90 (0.70 – 1.40) | 0.60 (0.40 – 0.70) | 0.40 (0.40 – 0.50) |
| p1 | 0.001\* | <0.001\* | 0.001\* |  |  |  |
| Sig. bet. groups | p2=0.277, p3<0.001\*, p4<0.001\* |  |  |  |
| D.B |  |  |  |  |  |  |
| Min. – Max. | 0.10 – 1.20 | 0.10 – 2.20 | 0.17 – 0.80 | 0.17 – 0.40 | H=37.228\* | <0.001\* |
| Mean ± SD. | 0.50 ± 0.29 | 0.47 ± 0.51 | 0.36 ± 0.15 | 0.23 ± 0.06 |
| Median (IQR) | 0.40 (0.30 – 0.70) | 0.30 (0.20 – 0.50) | 0.30 (0.23 – 0.40) | 0.20 (0.19 – 0.30) |
| p1 | 0.001\* | <0.001\* | 0.001\* |  |  |  |
| Sig. bet. groups | p20.010\*, p3=0.054, p4=0.475 |  |  |  |
| ALB |  |  |  |  |  |  |
| Min. – Max. | 2.40 – 5.0 | 2.30 – 4.70 | 3.80 – 5.20 | 4.0 – 5.50 | F=44.047\* | <0.001\* |
| Mean ± SD. | 3.71 ± 0.58 | 3.63 ± 0.61 | 4.35 ± 0.29 | 4.60 ± 0.50 |
| Median (IQR) | 3.75 (3.40 – 4.10) | 3.65 (3.20 – 4.0) | 4.30 (4.20 – 4.50) | 4.50 (4.0 – 5.0) |
| p1 | <0.001\* | <0.001\* | 0.095 |  |  |  |
| Sig. bet. groups | p2=0.785, p3<0.001\*, p4<0.001\* |  |  |  |
| AFP |  |  |  |  |  |  |
| Min. – Max. | 15.0 – 20010.0 | 8.0 – 7441.0 | 1.0 – 20.0 | 2.0 – 10.0 | H=126.642\* | <0.001\* |
| Mean ± SD. | 604.13 ± 3351.38 | 277.30 ± 1214.90 | 11.52 ± 6.27 | 5.90 ± 2.32 |
| Median (IQR) | 24.10 (15.90 – 29.0) | 14.0(10.0 – 16) | 10.70 (9.0 – 17.75) | 6.0 (4.50 – 8.0) |
| p1 | <0.001\* | <0.001\* | <0.001\* |  |  |  |
| Sig. bet. groups | P1<0.001\*, p2<0.001\*, p3=0.336 |  |  |  |
| PT |  |  |  |  |  |  |
| Min. – Max. | 55.10 – 100.0 | 55.0 – 100.0 | 55.0 – 100.0 | 85.0 – 100.0 | H=34.189\* | <0.001\* |
| Mean ± SD. | 77.65 ± 11.19 | 78.31 ± 14.69 | 78.37 ± 14.86 | 91.25 ± 4.49 |
| Median (IQR) | 78.0 (69.0 – 85.0) | 77.50 (65.0 – 90.0) | 77.50(65.0 – 91.5) | 91.0(88.0 – 93.50) |
| p1 | <0.001\* | <0.001\* | <0.001\* |  |  |  |
| Sig. bet. groups | p2=0.557, p3=0.529, p4=0.094 |  |  |  |
| INR |  |  |  |  |  |  |
| Min. – Max. | 0.90 – 1.60 | 1.0 – 1.50 | 1.0 – 2.0 | 1.0 – 1.23 | H=36.705\* | <0.001\* |
| Mean ± SD. | 1.10 ± 0.16 | 1.16 ± 0.13 | 1.09 ± 0.26 | 1.04 ± 0.08 |
| Median (IQR) | 1.0 (1.0 – 1.17) | 1.10 (1.10 – 1.20) | 1.0 (1.0 – 1.0) | 1.0 (1.0 – 1.0) |
| p1 | 0.039\* | <0.001\* | 0.790 |  |  |  |
| Sig. bet. groups | p2<0.001\*, p3=0.044\*, p4<0.001\* |  |  |  |
| Creatinine |  |  |  |  |  |  |
| Min. – Max. | 0.40 – 1.70 | 0.50 – 1.20 | 0.0 – 1.40 | 0.50 – 1.0 | 21.061\* | <0.001\* |
| Mean ± SD. | 0.84 ± 0.27 | 0.90 ± 0.19 | 0.91 ± 0.24 | 0.74 ± 0.18 |
| Median (IQR) | 0.80(0.6 – 1.0) | 0.90(0.8 – 1.1) | 1.0(0.9 – 1.0) | 0.70(0.6 – 0.95) |
| p1 | 0.042\* | <0.001\* | <0.001\* |  |  |  |
| Sig. bet. groups | p2=0.053, p3=0.012\*, p40.651 |  |  |  |

SD: Standard deviation IQR: Inter quartile range H: H for Kruskal Wallis testp: p value between the studied groups p1: between control and each other groups p2: between de-novo HCC and post-DAAs HCC **(**G1 & G2) p3: between de-novo HCC and DAAs treated HCV (G1 & G3) p4: between post-DAAs HCC and DAAs treated HCV (G2 & G3)\*: Statistically significant